PHIO - Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT) | Benzinga
MARLBOROUGH, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about its lead clinical product candidate, PH-762, an INTASYL compound.
Preclinical studies demonstrate that PH-762 is effective in silencing PD-1, boosting immune response, and inhibiting tumor growth. PH-762 is currently being studied in a U.S. clinical trial to assess safety and efficacy in specific skin cancers (NCT 06014086).
The data will be presented at the American Society of Cell and Gene Therapy (ASCGT) on May 8th in Baltimore, Maryland. The mission of ASGCT is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease.
Presentation Details are as follows:
| Title: |
| INTASYL PH-762: PD-1 Intratumoral Immunotherapy |
| Abstract Number: |
| 774 |
| Session Title: |
| Cancer-Immunotherapy and Cancer Vaccines |
| Authors: |
| Melissa Maxwell, Linda Mahoney, Mary Spellman |
| Date and Time: |
| May 8, 2024 at 12:00 PM EST |
| Location: |
| Exhibit Hall |
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (NASDAQ: